P&G Pharmaceuticals
In December 2004, TaiGen signed a licensing agreement with Procter & Gamble Pharmaceuticals to further the development and commercialization of a novel non-fluorinated quinolone Nemonoxacin to treat bacteria infection. TaiGen acquires the full development and commercialization rights for China, Taiwan, Hong Kong, Singapore, Korea and a total of 10 ASEAN countries. TaiGen is responsible for conducting Phase Ib and Phase II development of the compound outside this region.
In 2008, TaiGen's Phase II study of Nemonoxacin for Community Acquired Pneumonia (CAP) was completed successfully, having met the primary endpoint of non-inferiority to Levofloxacin, the leading quinolone on the market. TaiGen is now working on completing Phase II trials of Nemonoxacin for the treatment of Diabetic Foot Infection (DFI).
Academia Sinica
Academia Sinica, the most prestigious research institute in Taiwan has its campus within close proximity to TaiGen. Beginning in 2003, TaiGen has signed several collaborative agreements with the x-ray crystallography group at Academia Sinica for its drug discovery programs in antiviral and cancer fields. Under these agreements, Academia Sinica is responsible for developing the x-ray crystallography of drug lead/target protein complexes. The two parties have established an interactive and efficient collaboration structure; TaiGen provides funding for the research, while Academia Sinica in turn is entitled to receive payments when products from the collaboration are launched in the market.
Chang Gung Memorial Hospital
In the summer of 2002, TaiGen signed a collaborative agreement with Chang Gung Memorial Hospital (CGMH), the largest private hospital in Taiwan. Under the agreement, CGMH will make available to TaiGen hepatitis and cirrhotic liver tumor tissues from 7,000 cancer patients. TaiGen will conduct gene expressing profiling of these diseased tissues for drug target selection and validation. In 2004, TaiGen signed a second collaborative agreement with the hospital to conduct HCV drug screening by employing an in-vitro viral replication system developed by investigators at the hospital.
Contact:
John Jin, Vice President of Business Development
TaiGen Biotechnology Co., Ltd.
7F, 138 Shin Ming Rd., Neihu Dist., Taipei, Taiwan 114, R.O.C.
Tel. 886-2-2790-1861, ext. 1710 (Taipei Office)
Fax. 886-2-2796-3606 (Taipei Office)
johnjin@taigenbiotech.com.tw
Top
